Table 2.
Lifetime cost-effectiveness results for base case and scenario analyses
| Outcomes | Cost ($/￥) | Effectiveness (QALY or life-years) | ICER | % < 1 time of GDP/capita per QALY | % < 2 times of GDP/capital per QALY | % < 3 times of GDP/capita per QALY | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Enalapril-folic acid | Enalapril | ∆ | Enalapril-folic acid | Enalapril | ∆ | |||||
| Base case analyses | ||||||||||
| Quality-adjusted life-year |
$3903.69 ￥25,178.80 |
$2269.85 ￥14,640.53 |
$1633.84 ￥10,538.27 |
11.06 | 11.00 | 0.06 |
$26,066.13 ￥168,126.54 |
2.6% | 47.6% | 74.5% |
| Life-year |
$3903.69 ￥25,178.80 |
$2269.85 ￥14,640.53 |
$1633.84 ￥10,538.27 |
22.59 | 22.56 | 0.03 |
$61,770.73 ￥398,421.21 |
6.4% | 27.1% | 38.6% |
| Scenario analyses | ||||||||||
| Enalapril-folic acid at 1/2 cost |
$2788.79 ￥17,987.70 |
$2269.85 ￥14,640.53 |
$5018.94 ￥3347.16 |
11.06 | 11.00 | 0.06 |
$8279.10 ￥53,400.20 |
73.8% | 91.3% | 94.7% |
| Enalapril-folic acid has no benefit beyond year 5 |
$4034.69 ￥26,023.75 |
$2251.04 ￥14,519.21 |
$1783.66 ￥11,504.61 |
11.045 | 11.01 | 0.04 |
$45,246.92 ￥291,842.63 |
0 | 9.4% | 32.7% |
| Enalapril-folic acid has no benefit beyond year 10 |
$3965.16 ￥25,575.28 |
$2247.02 ￥14,493.28 |
$1718.15 ￥11,082.07 |
11.06 | 11.01 | 0.05 |
$33,012.65 ￥212,931.59 |
0.1% | 29.5% | 59.5% |
QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio